Bladder Cancer

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year.

What is Bladder Cancer?

Bladder cancer refers to the growth of a tumor within the lining of the bladder. In some cases, the tumor can invade surrounding tissue and spread to other parts of the body.

What Causes Bladder Cancer?

Bladder Cancer Diagnosis

Bladder Cancer Treatment

Bladder Cancer Types

Symptoms of Bladder Cancer

What is Intravesical Therapy?

Bladder Cancer Biomarkers

Bladder Cancer Histopathology

Endoscopic Imaging for Bladder Cancer

Thromboembolism in Bladder Cancer

Non-Invasive Diagnostic Strategies for Bladder Cancer

See more featured articles »

Bladder Cancer Genomics

Bladder Cancer Risk Factors

Muscle Invasive Bladder Cancer (MIBC)

Muscle Invasive Bladder Cancer (MIBC) Diagnosis and Treatment

Latest Bladder Cancer News and Research

Buy and bust: Collapse of private equity-backed rural hospitals mired employees in medical bills

The first unexpected bill arrived in December, just weeks before Tara Lovell's husband of 40 years died from bladder cancer.

16 Aug 2022

Biological sex differences may be the reason behind higher cancer risk among men than women

Rates of most types of cancer are higher in men than in women for reasons that are unclear. Results from a recent study published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, suggest that the cause may be underlying biological sex differences rather than behavioral differences related to smoking, alcohol use, diet, and other factors.

8 Aug 2022

UAB researchers report a potential treatment for ARID1A-deficient bladder cancer

Metastatic bladder cancer is generally incurable, so new therapies are an urgent need. Researchers at the University of Alabama at Birmingham now report a potential treatment for a quarter of bladder cancers.

4 Aug 2022

Genetic signatures may help predict immunotherapy response in patients with bladder cancer

Investigators from Cedars-Sinai Cancer have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy.

3 Aug 2022

Improving dialogue between healthcare professionals and patients in bladder cancer

In this interview, Dr. Ignacio Duran and Alex Filicevas focus on improving dialogue between healthcare professionals and patients, outlining ways in which we can encourage open discussion to improve the overall patient experience.

From Janssen Pharmaceuticals 1 Aug 2022

International Agency for Research on Cancer classifies firefighting as carcinogenic

The International Agency for Research on Cancer recently classified occupational exposure as a firefighter as carcinogenic, changing the previous classification of possibly carcinogenic.

20 Jul 2022

Network-based machine learning method helps predict cancer patients' response to immunotherapy

Immunotherapy is a new cancer treatment that activates the body's immune system to fight against cancer cells without using chemotherapy or radiotherapy.

12 Jul 2022

Study illustrates how the use of whole exome sequencing can better predict treatment response

Immunotherapies, such as immune checkpoint inhibitors, have transformed the treatment of advanced stage cancers.

8 Jul 2022

Discussing tools and resources to support the bladder cancer patient community

In this interview, Dr. Ignacio Durán and Alex Filicevas discuss key challenges and opportunities in the bladder cancer disease landscape and the future of care. This episode focuses on the bladder cancer patient support landscape, including a review of the tools and resources available to the community, as well as key unmet needs to address.

From Janssen Pharmaceuticals 4 Jul 2022

Understanding the impact of bladder cancer on daily life before and after diagnosis

In this interview, Dr. Ignacio Durán and Alex Filicevas, discuss key challenges and opportunities in the bladder cancer disease landscape and the future of care. They focus on the quality of life for patients and delve into the impact bladder cancer has on daily life, both before and after diagnosis and treatment, from the holistic perspective of both patients and HCPs.

From Janssen Pharmaceuticals 4 Jul 2022

Bladder cancer patients with ctDNA positivity respond very well to treatment with atezolizumab

Researchers who treated a group of post-surgery bladder cancer patients with the immunotherapy drug atezolizumab have found that patients whose blood contained circulating tumour DNA (ctDNA), responded very well to the treatment.

3 Jul 2022

Androgens contribute to sex bias in bladder cancer

Male sex hormones interfere with the body's ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study co-led by a Cedars-Sinai Cancer investigator.

10 Jun 2022

New initiative aims to increase collaboration and accelerate high-impact cancer immunotherapy

The accelerated advancement of cancer immunology and immunotherapy, a type of biological therapy that boosts the immune system's ability to recognize and kill cancer cells, has significantly improved the effectiveness of cancer treatment and patient outcomes.

25 May 2022

Robotic surgery reduces readmissions, benefits patients' overall recovery

A new study, published in JAMA, has found that robotic surgery reduces the chance of readmission by half (52 per cent), and revealed a "striking" four-fold (77 per cent) reduction in prevalence of blood clots (deep vein thrombus and pulmonary emboli) - a significant cause of health decline and morbidity - when compared to patients who had open surgery.

15 May 2022

Immunotherapy after bladder cancer surgery helps reduce cancer recurrence

Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association annual meeting in May.

15 May 2022

Penn study finds low uptake of first mutation-targeted bladder cancer drug

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

12 May 2022

Study shows effectiveness of point-of-care smoking cessation program for cancer patients

New research in the May 2022 issue of JNCCN-; Journal of the National Comprehensive Cancer Network finds the inclusion of the smoking cessation tool Electronic Health Record-Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE, from Epic) into electronic health records (EHRs) can increase self-reported patient quit rates by more than 5 percentage points.

11 May 2022